Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. : HP5-148/2022E-PDF
"On November 3, 2022, Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals 18 years of age and older"--Overview, page 3.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.916714&sl=1
| Ministère/Organisme | Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. |
|---|---|
| Titre | Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. |
| Variante du titre | Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Autres langues publiées | [Français] |
| Format | Électronique |
| Document électronique | |
| Note(s) | Issued also in French under title: Recommandations sur l'utilisation chez les adultes du vaccin de rappel à ARNm Spikevax bivalent BA.4/5 (50 mcg) de Moderna contre la COVID-19 : résumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022. Cover title. "Pub.: 220546." |
| Information sur la publication | Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, 2022. ©2022 |
| Description | 1 online resource (3 pages) |
| ISBN | 9780660460291 |
| Numéro de catalogue |
|
| Numéro de catalogue du ministère | 220546 |
| Descripteurs | COVID-19 (Disease) -- Vaccination -- Canada. COVID-19 (Disease) -- Vaccination -- Government policy -- Canada. |